



A Phase 1b Clinical Trial of
LY3537982 in Patients With Cancer
With a Specific Genetic Mutation
(KRAS G12C)

● Looking for participants

What is the purpose of this study?

To learn if **LY3537982** is safe and effective in patients with cancer who have a specific genetic mutation (KRAS G12C).

What is KRAS?

- **KRAS** is a gene that we all have. It helps our cells grow in a controlled way. In some people, the KRAS gene can change and stop working the right way. When this happens, cells in the body divide and can grow out of control. This can lead to lung cancer
- To check if the KRAS gene has changed, a doctor can perform **tests** using a sample of their patient's blood and/or tumor tissue

Who can participate in the study?

People who:

- Are 18 years old or older
- Have lung cancer with a change in the KRAS G12C gene that is advanced and/or has spread to another part of the body
- Are well enough to walk and do light work
- Are able to swallow capsules

Please visit the trial website for the complete list of eligibility criteria.


What are the goals of the study?

- To learn about the safety, side effects, and effectiveness of LY3537982

Please visit the trial website for the complete list of outcomes.

What is the study treatment plan?

- This will be an **open-label study**. This means that both doctors and study participants know what treatment they will get
- LY3537982 is the **investigational medicine**; this is the medicine being studied. It is a capsule(s) that you swallow. In this study, the investigational medicine will be given alone or with other cancer medicine(s) in one of the following combinations:



^aOral medicine given twice daily

^bThis medicine is given once every 3 weeks as an intravenous (IV) infusion, which slowly drips the medicine through a tiny tube directly into your vein

¹One of two dose amounts of LY3537982 will be given to patients twice daily

If you have lung cancer with a change in the KRAS G12C gene, consider learning more about this study.

- Print out and bring this sheet to your next appointment with your doctor
- Participants may receive reimbursement for approved travel costs
- Participants are free to leave the study at any point



For more information:

<https://trials.lilly.com/en-US/trial/295242>

LOXO @ Lilly

LOXO Trials Support: clinicaltrials@loxooncology.com

The use of LY3537982 is investigational. Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.



A Phase 1b Clinical Trial of
LY3537982 in Patients With Cancer
With a Specific Genetic Mutation
(KRAS G12C)

● Looking for participants

What is the purpose of this study?

To learn if **LY3537982** is safe and effective in patients with cancer who have a specific genetic mutation (KRAS G12C).

What is KRAS?

- **KRAS** is a gene that we all have. It helps our cells grow in a controlled way. In some people, the KRAS gene can change and stop working in the right way. When this happens, cells in the body divide and can grow out of control. This can lead to cancer
- To check if the KRAS gene has changed, a doctor can perform **tests** using a sample of their patient's blood and/or tumor tissue

Who can participate in the study?

People who:

- Are 18 years old or older
- Have a tumor with a change in the KRAS G12C gene that is advanced and/or has spread to another part of the body
- Are well enough to walk and do light work
- Are able to swallow capsules

Please visit the trial website for the complete list of eligibility criteria.


What are the goals of the study?

- To learn about the safety, side effects, and effectiveness of LY3537982

Please visit the trial website for the complete list of outcomes.

What is the study treatment plan?

- This will be an **open-label study**. This means that both doctors and study participants know what treatment they will get
- LY3537982 is the **investigational medicine**; this is the medicine being studied. It is a capsule(s) that you swallow. In this study, the investigational medicine will be given alone or with other cancer medicine(s) to patients with the following cancer types:



^aOral medicine given twice daily

^bThis medicine is given as an intravenous (IV) infusion, which slowly drips the medicine through a tiny tube directly into your vein

If you have colorectal cancer, pancreatic cancer, or other solid tumor with a change in the KRAS G12C gene, consider learning more about this study.

- Print out and bring this sheet to your next appointment with your doctor
- Participants may receive reimbursement for approved travel costs
- Participants are free to leave the study at any point



For more information:

<https://trials.lilly.com/en-US/trial/295242>

LOXO Trials Support: clinicaltrials@loxooncology.com

The use of LY3537982 is investigational. Not all risks are known. There is no guarantee that a participant's cancer will improve when taking part in this study.